Teva Pharmaceutical Industries Ltd (TEVJF) — SEC Filings
Teva Pharmaceutical Industries Ltd (TEVJF) — 29 SEC filings. Latest: 8-K (Dec 11, 2025). Includes 16 8-K, 6 10-Q, 2 DEF 14A.
View Teva Pharmaceutical Industries Ltd on SEC EDGAR
Overview
Teva Pharmaceutical Industries Ltd (TEVJF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: TEVA PHARMACEUTICAL INDUSTRIES LTD reported a significant turnaround in its financial performance for the three and nine months ended September 30, 2025. Net revenues increased to $4,480 million for the three months, up from $4,332 million in the prior year, and to $12,547 million for the nine month
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 27 neutral. The dominant filing sentiment for Teva Pharmaceutical Industries Ltd is neutral.
Filing Type Overview
Teva Pharmaceutical Industries Ltd (TEVJF) has filed 16 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 1 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of TEVJF's 23 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $4,480M |
| Net Income | $434M |
| EPS | $0.38 |
| Debt-to-Equity | 4.50 |
| Cash Position | $2,203M |
| Operating Margin | 19.7% |
| Total Assets | $39,856M |
| Total Debt | $32,602M |
Key Executives
- Israel
- Kare Schultz
- Richard Francis
- Dr. Ghiath Sharbain
- Ms. Sigal Rosenthal
- Mr. Michael McClellan
- Dr. Sol J. Barer
Industry Context
Teva operates in the highly competitive global pharmaceutical industry, with significant pressure from generic drug manufacturers and evolving regulatory landscapes. The industry is characterized by R&D intensity, patent cliffs, and increasing demand for affordable medicines. Companies like Teva must navigate complex pricing negotiations, supply chain challenges, and the constant need for innovation to maintain market share.
Top Tags
financial-reporting (7) · operations (3) · Pharmaceuticals (2) · corporate-governance (2) · shareholder-vote (2) · material-agreement (2) · debt-repayment (2) · goodwill-impairment (2) · sustainability-bonds (2) · executive-compensation (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net revenues (Q3 2025) | $4.48B | Increased from $4.332 billion in Q3 2024 |
| Net income (Q3 2025) | $434M | Swung from a net loss of $390 million in Q3 2024 |
| Net income (9 months 2025) | $937M | Reversed a net loss of $1,684 million in 9 months 2024 |
| Operating income (Q3 2025) | $882M | Improved from an operating loss of $51 million in Q3 2024 |
| Goodwill impairment (Q3 2024) | $600M | Zero in Q3 2025, a key driver of profitability turnaround |
| Goodwill impairment (9 months 2024) | $1.00B | Zero in 9 months 2025, significantly boosting net income |
| Cash and cash equivalents (Sept 30, 2025) | $2.20B | Decreased from $3.30 billion at Dec 31, 2024 |
| Repayment of senior notes and loans (9 months 2025) | $4.11B | Significant reduction in long-term debt |
| Senior notes and loans (Sept 30, 2025) | $16.77B | Still a substantial amount of long-term debt |
| Ordinary shares outstanding (Sept 30, 2025) | 1,147,282,512 | Reflects the total number of shares outstanding |
| Negative derivative impact on Q2 2025 revenues | $32M | Increased from $2M in Q2 2024, indicating heightened currency risk. |
| Negative derivative impact on H1 2025 revenues | $60M | Contrasts with a positive $10M impact in H1 2024, showing a significant reversal. |
| Senior notes issued in May 2025 | $700M | Adds to long-term debt, bearing 5.75% annual interest. |
| Increase in negative derivative impact (Q2 2024 to Q2 2025) | 1500% | Highlights a dramatic surge in currency-related losses. |
| Goodwill Impairment | $29.58B | As of March 31, 2025, indicating potential overvaluation of past acquisitions. |
Forward-Looking Statements
- {"claim":"Teva's interest expenses will increase due to sustainability-linked bonds.","entity":"Teva Pharmaceutical Industries Ltd.","targetDate":"September 15, 2026","confidence":"medium"}
- {"claim":"Teva will continue to pursue collaborations for its drug pipeline assets.","entity":"Teva Pharmaceutical Industries Ltd.","targetDate":"2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Teva Pharmaceutical Industries Ltd (TEVJF)?
Teva Pharmaceutical Industries Ltd has 29 recent SEC filings from Jan 2024 to Dec 2025, including 16 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TEVJF filings?
Across 29 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 27 neutral. The dominant sentiment is neutral.
Where can I find Teva Pharmaceutical Industries Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Teva Pharmaceutical Industries Ltd (TEVJF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Teva Pharmaceutical Industries Ltd?
Key financial highlights from Teva Pharmaceutical Industries Ltd's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TEVJF?
The investment thesis for TEVJF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Teva Pharmaceutical Industries Ltd?
Key executives identified across Teva Pharmaceutical Industries Ltd's filings include Israel, Kare Schultz, Richard Francis, Dr. Ghiath Sharbain, Ms. Sigal Rosenthal and 2 others.
What are the main risk factors for Teva Pharmaceutical Industries Ltd stock?
Of TEVJF's 23 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Teva Pharmaceutical Industries Ltd?
Recent forward-looking statements from Teva Pharmaceutical Industries Ltd include guidance on {"claim":"Teva's interest expenses will increase due to sustainability-linked bonds.","entity":"Teva Pharmaceutical Indu and 1 other predictions.